Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect of ASC41 in Healthy Volunteers
NCT04692025Phase 1Completed
- Sponsor
- Gannex Pharma Co., Ltd.
- Start
- Dec 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ASC-41 in Nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD) and hyperlipidemia (2 arms), sponsored by Gannex Pharma Co., Ltd. Primary endpoints: Area Under the Curve up to 19 days and Maximum Plasma Concentration up to 19 days. Started Dec 2020; status: completed.
02
Drugs
ASC-41
03
Conditions
Nonalcoholic steatohepatitis (NASH)non-alcoholic fatty liver disease (NAFLD)hyperlipidemia
Beyond the preview
Go deeper on NCT04692025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04692025.